• STAT+: With new data, J&J's CAR-T drug benefits myeloma patients with less advanced disease

    30 days ago - By STAT

    When doctors prescribe a personalized cell therapy today, the patient they're trying to help has blood cancer so advanced other medicines no longer work. In the future, these so-called CAR-T treatments might be used earlier, for greater benefit, when cancer patients aren't so desperately sick.
    Toward that goal, a CAR-T therapy called cilta-cel from Johnson & Johnson was more effective and better tolerated when used to treat patients with less advanced multiple myeloma, according to preliminary study results released Wednesday. Continue to STAT+ to read the full story...
    Read more ...

     

  • STAT+: Allogene's blood cancer data show durability of off-the-shelf CAR-T cells

    30 days ago - By STAT

    There's little disputing that an off-the-shelf CAR-T cell therapy for cancer would provide flexibility and convenience over bespoke CAR-T therapies already in use. But can these experimental treatments induce the same kind of durable responses?
    Allogene on Wednesday said its off-the-shelf CAR-T, called ALLO-501, maintained a 36% complete response rate at six months - an important measure of response durability - in patients with large B-cell lymphoma, a common and aggressive type of blood cancer. Continue to STAT+ to read the full story...
    Read more ...

     

  • STAT+: Iovance CEO abruptly resigns after FDA setback for its cancer cell therapy

    30 days ago - By STAT

    Hours after the biotech company Iovance announced yet another regulatory delay for its investigational cancer treatment, the firm disclosed Wednesday that its CEO had abruptly tendered her resignation, sending its share price plummeting.
    Maria Fardis, who has run Iovance since 2016, informed the company on Tuesday that she “will be resigning” from her roles as CEO, president, and board member, the firm said in a two-sentence filing with the Securities and Exchange Commission. Iovance did not specify whether Fardis's resignation was effective immediately, and the company did not immediately...
    Read more ...